ENTITY
New Horizon Health

New Horizon Health (6YZ GR)

61
Analysis
Health Care • China
New Horizon Health Limited is a China-based investment holding company focused on early cancer screening and in-home testing, with an emphasis on colorectal, gastric, and cervical cancers. Its key products include ColoClear and Pupu Tube. The company was founded in 2015 and is headquartered in Hangzhou, China.
more
•15 Feb 2021 15:22

SciClone Pharmaceutical IPO: Future Prospects for Zadaxin Troubling

SciClone Pharmaceuticals, a biopharmaceutical company with an integrated platform for product development and commercialisation has filed for an...

Share
•10 Feb 2021 11:20

Joinn Laboratories IPO: Pioneer of Commercial GLP Laboratories in China Shows Promise

Joinn Laboratories, a non-clinical CRO focused on drug safety assessment has filed for a secondary listing on the Hong Kong Stock Exchange and...

Share
bullish•New Horizon Health
•08 Feb 2021 09:26

New Horizon Health IPO Valuation: Healthy Valuation

The company has set the terms for its IPO, where it plans to raise net proceeds of US$176-208m (approx. HK$1.4-1.6bn) through the issuance of 76.6m...

Share
•07 Feb 2021 15:13

Suzhou Basecare Medical IPO: Trading Debut

Basecare priced its IPO at HK$27.36 and closed 14% up at HK$31.20 in the grey market. Our DCF sensitivity analysis shows that the IPO price is...

Logo
468 Views
Share
bullish•Kuaishou Technology
•07 Feb 2021 10:01

ECM Weekly (7 February 2021) - Kuaishou, New Horizon, SciClone, Cloopen

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
x